Works matching IS 2160763X AND DT 2014 AND VI 3 AND IP 3
Results: 13
An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 229, doi. 10.1002/cpdd.97
- By:
- Publication type:
- Article
Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 179, doi. 10.1002/cpdd.79
- By:
- Publication type:
- Article
Sleep-promoting medications: Weighing the hazards of use versus non-use.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting β-agonist, in children aged 5-11 years with persistent asthma: A randomized trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 215, doi. 10.1002/cpdd.92
- By:
- Publication type:
- Article
Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 235, doi. 10.1002/cpdd.96
- By:
- Publication type:
- Article
No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 187, doi. 10.1002/cpdd.78
- By:
- Publication type:
- Article
Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 242, doi. 10.1002/cpdd.80
- By:
- Publication type:
- Article
The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 202, doi. 10.1002/cpdd.91
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. i, doi. 10.1002/cpdd.66
- Publication type:
- Article
Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 207, doi. 10.1002/cpdd.90
- By:
- Publication type:
- Article
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 222, doi. 10.1002/cpdd.94
- By:
- Publication type:
- Article
Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 170, doi. 10.1002/cpdd.98
- By:
- Publication type:
- Article
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 194, doi. 10.1002/cpdd.93
- By:
- Publication type:
- Article